Other languages Xilio Therapeutics, Inc.

Equities

XLO

US98422T1007

Delayed Nasdaq Other stock markets 12:45:26 2024-05-08 pm EDT			5-day change	1st Jan Change
1.191 ^USD	-5.49%		+10.26%	+116.51%

Apr. 19	Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says	MT
Apr. 01	Xilio Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Xilio Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Apr. 01
Xilio Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01
Sector Update: Health Care Stocks Slide Late Afternoon	Apr. 01
Top Midday Gainers	Apr. 01
Signs of Softening Inflation Fuel Narrow Premarket Gains for US Equity Futures	Apr. 01
Top Premarket Gainers	Apr. 01
Wall Street Set to Open Flat in Thursday Trading; Q4 US GDP Revised Up, Weekly Jobless Claims Fall	Mar. 28
Gilead Sciences Signs Exclusive Development, Commercialization License for Xilio's Tumor-Activated IL-12	Mar. 28
Xilio Therapeutics, Inc. Enters Exclusive License Agreement with Gilead Sciences, Inc	Mar. 28
Xilio Therapeutics, Inc. Plans Workforce Reduction	Mar. 28
Xilio Therapeutics, Inc. Reports Additional Data from Its Phase 2 Clinical Trial Evaluating XTX202	Mar. 28
Xilio Therapeutics, Inc. Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101	Dec. 07
Xilio Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09
Xilio Therapeutics Shares Rise Following Initial Phase 1/2 Data on XTX202	Nov. 03
Xilio Therapeutics, Inc. Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202	Nov. 03
Xilio Therapeutics Announces Board Changes	23-09-05
Xilio Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14
Xilio Therapeutics Names New Chief Operating Officer	23-08-04
Xilio Therapeutics, Inc. Announces Promotion of Chris Frankenfield to Chief Operating Officer	23-08-03
Xilio Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Xilio Therapeutics, Inc.

Equities

XLO

US98422T1007

Other languages

Filters